TYO:4588

Oncolys Biopharma Stock Predictions

Healthcare > Biotechnology

Buy 4588

*Your capital is at risk

JP¥2,849.00

+1.00 (+0.0351%)

At Close: Aug 10, 2026

Currently predicting for Wed, 12 Aug 2026

4588.T Live board

Community Bull/Bear

Target Next close

Join the 4588.T prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

4588.T Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For 4588.T

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

4588.T Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	JPY target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT ONCOLYS BIOPHARMA INC.

Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
GPOR $158.45	6.03%	Aug 06
FCX $62.63	12.61%	Jul 31
BIIB $202.19	2.44%	Jul 24
TSCO $30.32	14.18%	Jul 23
S SW $43.71	8.88%	Jul 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by